Most cancer vaccines are designed to activate tumor-specific CD8+ cytotoxic T cells, so the most common peptide vaccination strategy is based on MHC class I-restricted peptide epitopes on TAA (Butterfield, 2015). This evidence concerns the gene CD8A and cancer.